{"prompt": "['Alliance A221504', '3.2.7 Patients must have used opioid medication(s) for pain at some time in the 4', 'weeks prior to registration. Current use of opioids (at the time of registration)', 'and/or later during the course of the study is permitted but not required.', '3.2.8', 'Expected survival > 3 months.', '3.2.9', 'No concurrently active second invasive malignancies except non-melanoma', 'skin cancer. (See Section 3.1 for definitions).', '3.2.10 No history of gastrointestinal obstruction, or conditions that increase the risk', 'of gastrointestinal obstruction, perforation, bleeding or impairment of the', 'gastrointestinal wall. No abdominal surgery within 60 days of registration.', '3.2.11 No acute gastrointestinal conditions, such as: obstruction, fecal impaction,', 'obstipation, acute surgical abdomen, ongoing need for manual maneuvers to', 'induce bowel movements (such as digital evacuation).', '3.2.12', 'No conditions that may compromise blood-brain barrier permeability (e.g.,', \"multiple sclerosis, recent brain trauma, Alzheimer's disease, or uncontrolled\", 'seizures).', 'No symptomatic and untreated brain metastases. Patients will be eligible for', 'study if radiation therapy for brain metastases was completed at least 7 days', 'prior to registration.', 'Patients having received stereotactic radiation will be eligible if the radiation', 'was completed at least 7 days prior to registration.', 'Patients having undergone surgical resection of brain metastases will be', 'eligible after they have healed and recovered from the surgical intervention', 'sufficiently to start systemic treatment for NSCLC, as determined by a', 'neurosurgeon.', 'No known leptomeningeal carcinomatosis.', '3.2.13 No history of myocardial infarction 6 months prior to registration. No', 'current symptomatic congestive heart failure, uncontrolled angina or', 'uncontrolled cardiac arrhythmias.', '3.2.14 No severe hepatic impairment (Child-Pugh class C) or acute liver disease.', '3.2.15 No known serious or severe hypersensitivity reaction to naloxegol or any of', 'its excipients. See list of excipients in Section 10.1.', '3.2.16 No concurrent use of moderate/strong CYP3A4 inhibitors, or strong CYP3A4', 'inducers. (See Sections 8.1.5 and 8.1.6)', '3.2.17 Not pregnant and not nursing, because this study involves an investigational', 'agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus', 'and newborn are unknown.', 'Therefore, for women of childbearing potential only, a negative pregnancy', 'test done 7 days prior to registration is required. A female of childbearing', 'potential is a sexually mature female who: 1) has not undergone a hysterectomy or', 'bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least', '12 consecutive months (i.e., has had menses at any time in the preceding 12', 'consecutive months).', '18', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', '3.2.18 Age 18 years', '3.2.19 ECOG Performance Status 0-2', '3.2.20 Required Initial Laboratory Values:', 'Absolute Neutrophil Count (ANC)', '> 1,500/mm\u00b3', 'Platelet Count', '> 100,000/mm\u00b3', 'Calc. Creatinine Clearance', '> 60 mL/min *', 'Total Bilirubin', 'VI 1.2 x upper limit of normal (ULN)**', 'AST and ALT', 'VI 2.5 x upper limit of normal (ULN)', '* Calculated using the Cockcroft-Gault formula', \"** *Unless due to Gilbert's disease\", '19', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}